Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing-Reference-Cited by-同舟云学术

Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing

Published:2023-10-31 Issue:1 Volume:24 Page:
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Xia Yuxue¹²^ORCID,Zhang Lu¹,He Wenjuan¹,Pan Huaxiong³,Fang Jun¹,Cui Guohui¹

Affiliation:

1. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

2. Department of Hematology, Dabieshan District Medical Center, Huanggang, China

3. Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2023.2271212

Reference17 articles.

1. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

2. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer

3. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

4. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature

5. ALK-positive Large B-cell Lymphoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2023-12-16